MCID: END041
MIFTS: 63

Endometrial Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Adenocarcinoma

MalaCards integrated aliases for Endometrial Adenocarcinoma:

Name: Endometrial Adenocarcinoma 12 15 70
Endometrial Endometrioid Adenocarcinoma 12 17 70
Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation 6 17
Endometrial Adenoacanthoma 12 70
Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation 12
Endometrioid Carcinoma of Endometrium 12
Endometrioid Adenomas and Carcinomas 12
Adenocarcinoma of the Endometrium 12
Endometrioid Adenoma or Carcinoma 12
Adenocarcinoma of Endometrium 12
Endometrium Adenocarcinoma 17
Adenocarcinoma of Uterus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2870
SNOMED-CT 67 123845008 762458004
UMLS 70 C0279763 C1153706 C1336905

Summaries for Endometrial Adenocarcinoma

Disease Ontology : 12 An endometrial carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Endometrial Adenocarcinoma, also known as endometrial endometrioid adenocarcinoma, is related to endometrial mucinous adenocarcinoma and adenomyosis. An important gene associated with Endometrial Adenocarcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Gene Expression and ERK Signaling. The drugs Dexmedetomidine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include breast, uterus and ovary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Endometrial Adenocarcinoma

Diseases related to Endometrial Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 609)
# Related Disease Score Top Affiliating Genes
1 endometrial mucinous adenocarcinoma 32.2 PGR CDKN2A
2 adenomyosis 31.1 VEGFA TP53 PGR ESR2 ESR1
3 papillary serous adenocarcinoma 31.1 TP53 PGR KRT7 KRAS
4 endometrial hyperplasia 31.0 VEGFA TP53 PTEN PGR MLH1 KRAS
5 estrogen excess 30.8 PTEN PGR ESR2 ESR1
6 endocervical adenocarcinoma 30.8 TP53 PGR KRT7 ESR1 CDKN2A
7 adenocarcinoma 30.7 VEGFA TP53 PTEN MLH1 MALAT1 KRT7
8 cystadenoma 30.7 PTEN PGR KRT7
9 papillary adenocarcinoma 30.7 TP53 PGR KRT7 KRAS
10 adenomyoma 30.6 PGR MLH1 KRT7 CDKN2A
11 endometrial serous adenocarcinoma 30.6 TP53 PTEN PGR KRAS ESR1
12 appendix adenocarcinoma 30.6 KRT7 KRAS
13 bizarre leiomyoma 30.5 TP53 PGR ESR1 CDKN2A
14 leiomyosarcoma 30.5 VEGFA TP53 PGR ESR1 CDKN2A
15 endometriosis 30.5 VEGFA PTEN PGR MIR200A ESR2 ESR1
16 adenosquamous carcinoma 30.5 TP53 PTEN KRT7 KRAS EGFR CDKN2A
17 carcinosarcoma 30.5 TP53 PTEN PGR KRT7 KRAS EGFR
18 pseudomyxoma peritonei 30.5 TP53 KRT7 KRAS
19 fallopian tube carcinoma 30.4 VEGFA TP53 PTEN PGR ESR1
20 adenosarcoma 30.4 TP53 PGR ESR1
21 tuberous sclerosis 30.4 VEGFA TP53 PTEN AKT1
22 signet ring cell adenocarcinoma 30.4 TP53 MLH1 KRT7 KRAS
23 endometriosis of ovary 30.3 PGR ESR2 ESR1
24 teratoma 30.3 TP53 PTEN KRT7 KRAS CDKN2A AKT1
25 adenocarcinoma in situ 30.3 KRT7 KRAS EGFR CDKN2A
26 ovarian clear cell adenocarcinoma 30.3 VEGFA TP53 ESR2
27 adenoma 30.3 TP53 MLH1 KRT7 KRAS CDKN2A AKT1
28 endosalpingiosis 30.3 PGR KRT7 KRAS
29 cervical adenocarcinoma 30.3 TP53 PTEN KRT7 KRAS ESR1 EGFR
30 lynch syndrome 30.3 TP53 PTEN MLH1 KRAS EGFR CDKN2A
31 bilateral breast cancer 30.3 TP53 PTEN PGR MLH1 ESR1 CDKN2A
32 cystic teratoma 30.3 TP53 PTEN KRT7 KRAS CDKN2A
33 mature teratoma 30.2 TP53 KRT7 KRAS
34 tubular adenocarcinoma 30.2 PGR KRT7 ESR1 EGFR
35 intravenous leiomyomatosis 30.2 PGR ESR1
36 basal cell nevus syndrome 30.2 TP53 PTEN EGFR AKT1
37 appendiceal neoplasm 30.2 KRT7 KRAS
38 renal cell carcinoma, papillary, 1 30.2 VEGFA TP53 PTEN KRT7 EGFR CDKN2A
39 endometrioid ovary carcinoma 30.2 TP53 PTEN MLH1 KRAS
40 ovarian disease 30.1 VEGFA TP53 PTEN PGR MIR200A ESR2
41 endometrial stromal sarcoma 30.1 TP53 PGR MALAT1 ESR2 ESR1
42 in situ carcinoma 30.1 TP53 PTEN PGR MIR193A ESR1 EGFR
43 squamous cell papilloma 30.1 TP53 CDKN2A
44 pleomorphic adenoma 30.0 TP53 KRT7 CDKN2A
45 mucinous adenocarcinoma 30.0 VEGFA TP53 PGR MLH1 KRT7 KRAS
46 transitional cell carcinoma 29.9 TP53 PTEN MLH1 KRT7 EGFR CDKN2A
47 uterine corpus cancer 29.9 TP53 PTEN PGR MLH1 KRAS ESR1
48 ovarian clear cell carcinoma 29.9 VEGFA TP53 PTEN MLH1 KRT7 KRAS
49 papilloma 29.9 VEGFA TP53 PTEN KRT7 KRAS EGFR
50 colorectal adenocarcinoma 29.9 VEGFA TP53 PTEN MLH1 KRT7 KRAS

Graphical network of the top 20 diseases related to Endometrial Adenocarcinoma:



Diseases related to Endometrial Adenocarcinoma

Symptoms & Phenotypes for Endometrial Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.05 EGFR KRAS
2 Decreased viability GR00055-A-2 10.05 EGFR KRAS
3 Decreased viability GR00055-A-3 10.05 KRAS
4 Decreased viability GR00106-A-0 10.05 KRAS
5 Decreased viability GR00173-A 10.05 PIK3R2
6 Decreased viability GR00221-A-1 10.05 AKT1 CDKN2A EGFR ESR1 PIK3R2 KRAS
7 Decreased viability GR00221-A-2 10.05 AKT1 ESR1 PIK3R2 KRAS
8 Decreased viability GR00221-A-3 10.05 AKT1 CDKN2A
9 Decreased viability GR00221-A-4 10.05 AKT1 CDKN2A EGFR ESR1 PIK3R2
10 Decreased viability GR00249-S 10.05 AKT1 PIK3R2
11 Decreased viability GR00301-A 10.05 PIK3R2 KRAS
12 Decreased viability GR00381-A-1 10.05 KRAS
13 Decreased viability GR00386-A-1 10.05 ESR1
14 Decreased viability GR00402-S-2 10.05 ESR1

MGI Mouse Phenotypes related to Endometrial Adenocarcinoma:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
2 cellular MP:0005384 10.4 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
3 cardiovascular system MP:0005385 10.37 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
4 endocrine/exocrine gland MP:0005379 10.34 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
5 immune system MP:0005387 10.34 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
6 hematopoietic system MP:0005397 10.33 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
7 integument MP:0010771 10.29 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
8 digestive/alimentary MP:0005381 10.27 CDKN2A EGFR ESR1 ESR2 FGFR2 KRAS
9 embryo MP:0005380 10.27 AKT1 CDKN2A EGFR ESR1 FGFR2 KRAS
10 neoplasm MP:0002006 10.25 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
11 muscle MP:0005369 10.23 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
12 liver/biliary system MP:0005370 10.18 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
13 limbs/digits/tail MP:0005371 10.15 EGFR ESR1 ESR2 FGFR2 KRAS PGR
14 normal MP:0002873 10.07 AKT1 EGFR ESR1 ESR2 FGFR2 KRAS
15 no phenotypic analysis MP:0003012 10.06 CDKN2A EGFR ESR1 ESR2 FGFR2 KRAS
16 reproductive system MP:0005389 9.93 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
17 renal/urinary system MP:0005367 9.91 EGFR ESR1 ESR2 FGFR2 KRAS KRT7
18 pigmentation MP:0001186 9.8 CDKN2A EGFR FGFR2 KRAS PTEN TP53
19 respiratory system MP:0005388 9.7 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2
20 skeleton MP:0005390 9.36 AKT1 CDKN2A EGFR ESR1 ESR2 FGFR2

Drugs & Therapeutics for Endometrial Adenocarcinoma

Drugs for Endometrial Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4 Adrenergic alpha-Agonists Phase 4
5 Anesthetics Phase 4
6 Hypnotics and Sedatives Phase 4
7 Anesthetics, Dissociative Phase 4
8 Anesthetics, General Phase 4
9 Excitatory Amino Acid Antagonists Phase 4
10 Anesthetics, Intravenous Phase 4
11 Adrenergic Agonists Phase 4
12 Anesthetics, Local Phase 4
13 Adrenergic Agents Phase 4
14 Neurotransmitter Agents Phase 4
15 Analgesics Phase 4
16 Analgesics, Non-Narcotic Phase 4
17
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Epirubicin Approved Phase 3 56420-45-2 41867
20
Lenograstim Approved, Investigational Phase 3 135968-09-1
21
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
22
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
23
Liposomal doxorubicin Phase 3 31703
24 Antibiotics, Antitubercular Phase 3
25 Anti-Bacterial Agents Phase 3
26 Immunologic Factors Phase 3
27 Adjuvants, Immunologic Phase 3
28 Albumin-Bound Paclitaxel Phase 2, Phase 3
29 Hypoglycemic Agents Phase 2, Phase 3
30 Hormones Phase 3
31 Hormone Antagonists Phase 3
32 Estrogens Phase 3
33 Estrogens, Conjugated (USP) Phase 3
34
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
35
Gemcitabine Approved Phase 2 95058-81-4 60750
36
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
37
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
38
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
39
Nintedanib Approved Phase 2 656247-17-5 56843413
40
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
41
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
42
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
43
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
44
nivolumab Approved Phase 2 946414-94-4
45
Levonorgestrel Approved, Investigational Phase 2 797-63-7, 17489-40-6 13109
46
Pembrolizumab Approved Phase 2 1374853-91-4
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
50
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
2 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
3 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
4 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
7 A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Recruiting NCT04214067 Phase 3
8 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
9 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
10 A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma Terminated NCT00002976 Phase 3 conjugated estrogens
11 The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy Unknown status NCT02335203 Phase 2 Depot medroxyprogesterone acetate
12 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
13 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT02697591 Phase 1, Phase 2 INCAGN01876
14 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed NCT02923349 Phase 1, Phase 2 INCAGN01949
15 A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
16 Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer Completed NCT00870337 Phase 2 everolimus
17 A Phase II Study of Letrozole in Patients With Advanced or Recurrent Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
18 Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
19 A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium Completed NCT00030485 Phase 2 erlotinib hydrochloride
20 A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma Completed NCT00087100 Phase 2 pemetrexed disodium
21 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed NCT01877564 Phase 2 Metformin
22 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
23 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
24 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
25 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
26 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
27 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
28 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
29 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
30 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
31 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
32 A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00095979 Phase 2 ixabepilone
33 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
34 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
35 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
36 A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy Completed NCT00006089 Phase 2
37 Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma. Completed NCT03540407 Phase 2
38 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Completed NCT01968317 Phase 2 Megestrol acetate and metformin;Megestrol acetate
39 A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer Recruiting NCT02684227 Phase 2 Carboplatin;Enzalutamide;Paclitaxel
40 Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium Recruiting NCT03643510 Phase 2 Fulvestrant;Abemaciclib
41 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
42 A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium Active, not recruiting NCT01686126 Phase 2 Levonorgestrel;Metformin
43 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Active, not recruiting NCT00492778 Phase 2 Cisplatin
44 A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Active, not recruiting NCT02728258 Phase 2 Copanlisib
45 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
46 A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma Active, not recruiting NCT02730923 Phase 1, Phase 2 AZD2014;Anastrozole
47 Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma Active, not recruiting NCT02549209 Phase 2 Pembrolizumab;Paclitaxel;Carboplatin
48 Phase II Study of Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Stage I Endometrial Adenocarcinoma With Grade 2 Differentiation or Superficial Myomectomy Invasion Not yet recruiting NCT03567655 Phase 2 Farlutal tab. 500mg/ Pfizer
49 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma Suspended NCT03348631 Phase 2 Tazemetostat
50 Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer Terminated NCT01164150 Phase 2

Search NIH Clinical Center for Endometrial Adenocarcinoma

Genetic Tests for Endometrial Adenocarcinoma

Anatomical Context for Endometrial Adenocarcinoma

MalaCards organs/tissues related to Endometrial Adenocarcinoma:

40
Breast, Uterus, Ovary, Lymph Node, Cervix, Lung, Bone

Publications for Endometrial Adenocarcinoma

Articles related to Endometrial Adenocarcinoma:

(show top 50) (show all 2972)
# Title Authors PMID Year
1
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
2
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. 6
23908597 2013
3
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. 6
23002168 2012
4
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. 6
22885469 2012
5
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. 6
22238366 2012
6
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. 6
21984976 2011
7
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. 6
19853286 2010
8
Drug-sensitive FGFR2 mutations in endometrial carcinoma. 6
18552176 2008
9
Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. 47
19077565 2009
10
Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors. 61
33551199 2021
11
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. 61
33622671 2021
12
Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy. 61
33592112 2021
13
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. 61
33762086 2021
14
Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy. 61
32580640 2021
15
Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy. 61
33741653 2021
16
Analysis of microRNA regulating cell cycle-related tumor suppressor genes in endometrial cancer patients. 61
33123872 2021
17
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. 61
33563487 2021
18
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. 61
33766814 2021
19
Pharmacological inhibition of 17β-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model. 61
33762202 2021
20
Risk of incidental genital tract malignancies at the time of myomectomy and hysterectomy for benign conditions. 61
33321560 2021
21
Feasibility of intravoxel incoherent motion diffusion-weighted imaging in distinguishing adenocarcinoma originated from uterine corpus or cervix. 61
32671441 2021
22
The prevalence, genotype distribution of human papillomavirus and cervical cytology in Wenzhou, China: a retrospective research of 7391 cases. 61
32965784 2021
23
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. 61
33377972 2021
24
Tumor Evolution in a Patient with Recurrent Endometrial Cancer and Synchronous Neuroendocrine Cancer and Response to Checkpoint Inhibitor Treatment. 61
32945065 2021
25
Lynch syndrome or hereditary non polyposis colorectal cancer (HNPCC) in a moroccan family: Case report. 61
33520207 2021
26
A 20-year latency between hysterectomy for endometrial adenocarcinoma and solitary pulmonary metastasis: a case report. 61
33575026 2021
27
Mesonephric-Like Adenocarcinoma of the Endometrium: Diagnostic Advances to Spot This Wolf in Sheep's Clothing. A Review of the Literature. 61
33670088 2021
28
Expression of WW domain-containing oxidoreductase and its clinical implication in endometrial adenocarcinoma patients with metabolic syndrome. 61
33629514 2021
29
Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma. 61
33006785 2021
30
A case of Endometrioid endometrial adenocarcinoma with synchronous low-grade Appendiceal mucinous neoplasm and Pseudomyxoma peritonei. 61
33605928 2021
31
Spontaneous Evisceration of Incisional Hernia with Strangulation of Small Bowel: A Life Threatening Complication. 61
33623721 2021
32
Neoadjuvant radiotherapy and brachytherapy in endometrial cancer with gross cervical involvement: a CHIRENDO research group study. 61
33127863 2021
33
Relevance of lipogenesis and AMPK/Akt/mTOR signaling pathway in endometrial cancer. 61
33577023 2021
34
Violaceous nodules in a patient with endometrial adenocarcinoma. 61
33318990 2021
35
Elevated expression of EP4 in human decidua is associated with delayed embryo expulsion during medical abortion by promoting decidual cell proliferation. 61
30810415 2021
36
Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma. 61
33658856 2021
37
Effects of Vitamin D Analogs Alfacalcidol and Calcitriol on Cell Proliferation and Migration of HEC1A Endometrial Adenocarcinoma Cells. 61
32400204 2021
38
Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes. 61
32655012 2020
39
Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report. 61
32860769 2020
40
18F-FDG PET/CT Findings of an Isolated Splenic Metastasis From Endometrial Adenocarcinoma. 61
32956116 2020
41
Expression of Cyclin D1 in Hyperplasia and Carcinoma of Endometrium and Its Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features. 61
33268933 2020
42
Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression. 61
33193855 2020
43
Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment. 61
33159014 2020
44
Medroxyprogesterone Reverses Tolerable Dose Metformin-Induced Inhibition of Invasion via Matrix Metallopeptidase-9 and Transforming Growth Factor-β1 in KLE Endometrial Cancer Cells. 61
33172126 2020
45
Non-invasive Differentiation of Endometrial Adenocarcinoma from Benign Lesions in the Uterus by Utilization of Amide Proton Transfer-Weighted MRI. 61
33185840 2020
46
Robotic-Assisted Laparoscopic Hysterectomy for Endometrial Hyperplasia or Grade 1 Endometrial Adenocarcinoma: A 10-year, Single-Centre Experience. 61
33259942 2020
47
Possibility of Targeting Claudin-2 in Therapy for Human Endometrioid Endometrial Carcinoma. 61
32548807 2020
48
Expression of cyclooxygenase-2 in imprint smears of endometrial carcinoma. 61
32433831 2020
49
Peritoneal well-differentiated papillary mesothelioma coexisting with endometrial adenocarcinoma mimicking peritoneal carcinomatosis: A case report. 61
33218424 2020
50
Undifferentiated endometrial carcinoma arising in the background of high-grade endometrial carcinoma - Expanding the definition of dedifferentiated endometrial carcinoma. 61
32557836 2020

Variations for Endometrial Adenocarcinoma

ClinVar genetic disease variations for Endometrial Adenocarcinoma:

6 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIK3R2 NM_005027.4(PIK3R2):c.1681A>G (p.Asn561Asp) SNV Likely pathogenic 376165 rs1057519801 GRCh37: 19:18278061-18278061
GRCh38: 19:18167251-18167251
2 EGFR NM_005228.5(EGFR):c.2068G>A (p.Glu690Lys) SNV Likely pathogenic 376152 rs1057519794 GRCh37: 7:55241620-55241620
GRCh38: 7:55173927-55173927
3 FGFR2 NM_000141.5(FGFR2):c.1975A>G (p.Lys659Glu) SNV Likely pathogenic 376153 rs1057519795 GRCh37: 10:123247516-123247516
GRCh38: 10:121488002-121488002
4 FGFR2 NM_000141.5(FGFR2):c.1605G>A (p.Met535Ile) SNV Likely pathogenic 376164 rs1057519800 GRCh37: 10:123258076-123258076
GRCh38: 10:121498562-121498562
5 FGFR2 NM_000141.5(FGFR2):c.1690G>A (p.Val564Ile) SNV Likely pathogenic 376155 rs1057519797 GRCh37: 10:123256219-123256219
GRCh38: 10:121496705-121496705
6 FGFR2 NM_000141.5(FGFR2):c.1605G>T (p.Met535Ile) SNV Likely pathogenic 376162 rs1057519800 GRCh37: 10:123258076-123258076
GRCh38: 10:121498562-121498562
7 FGFR2 NM_000141.5(FGFR2):c.1611G>T (p.Met537Ile) SNV Likely pathogenic 376159 rs1057519799 GRCh37: 10:123258070-123258070
GRCh38: 10:121498556-121498556
8 FGFR2 NM_000141.5(FGFR2):c.1849T>A (p.Leu617Met) SNV Likely pathogenic 376154 rs1057519796 GRCh37: 10:123256060-123256060
GRCh38: 10:121496546-121496546
9 FGFR2 NM_000141.5(FGFR2):c.1647T>G (p.Asn549Lys) SNV Likely pathogenic 376156 rs121913476 GRCh37: 10:123258034-123258034
GRCh38: 10:121498520-121498520
10 FGFR2 NM_000141.5(FGFR2):c.1605G>C (p.Met535Ile) SNV Likely pathogenic 376163 rs1057519800 GRCh37: 10:123258076-123258076
GRCh38: 10:121498562-121498562
11 FGFR2 NM_000141.5(FGFR2):c.1611G>C (p.Met537Ile) SNV Likely pathogenic 376160 rs1057519799 GRCh37: 10:123258070-123258070
GRCh38: 10:121498556-121498556
12 FGFR2 NM_000141.5(FGFR2):c.1611G>A (p.Met537Ile) SNV Likely pathogenic 376161 rs1057519799 GRCh37: 10:123258070-123258070
GRCh38: 10:121498556-121498556
13 FGFR2 NM_000141.5(FGFR2):c.1639A>G (p.Ile547Val) SNV Likely pathogenic 376158 rs1057519798 GRCh37: 10:123258042-123258042
GRCh38: 10:121498528-121498528
14 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Likely pathogenic 13272 rs79184941 GRCh37: 10:123279677-123279677
GRCh38: 10:121520163-121520163
15 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) SNV Likely pathogenic 13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
16 FGFR2 NM_000141.5(FGFR2):c.1645A>C (p.Asn549His) SNV Likely pathogenic 374821 rs1057519045 GRCh37: 10:123258036-123258036
GRCh38: 10:121498522-121498522
17 FGFR2 NM_000141.5(FGFR2):c.1647T>A (p.Asn549Lys) SNV Likely pathogenic 376157 rs121913476 GRCh37: 10:123258034-123258034
GRCh38: 10:121498520-121498520
18 FGFR2 NM_000141.5(FGFR2):c.1694A>G (p.Glu565Gly) SNV Likely pathogenic 374823 rs121918506 GRCh37: 10:123256215-123256215
GRCh38: 10:121496701-121496701

Cosmic variations for Endometrial Adenocarcinoma:

9 (show top 50) (show all 13016)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264503 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 12
2 COSM88264271 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 12
3 COSM88264495 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 12
4 COSM87271104 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 12
5 COSM87278520 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8029G>A p.E2677K 16:72794653-72794653 12
6 COSM102036325 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.762G>T p.E254D 16:72829804-72829804 12
7 COSM87274708 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 12
8 COSM87281210 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4072T>G p.S1358A 16:72798610-72798610 12
9 COSM87291966 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 12
10 COSM102036916 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3865C>T p.R1289C 16:72796075-72796075 12
11 COSM149332944 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 12
12 COSM87284078 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 12
13 COSM149265473 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8512G>A p.V2838I 16:72794170-72794170 12
14 COSM87289878 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 12
15 COSM102020191 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1387C>A p.L463I 16:72798553-72798553 12
16 COSM149320029 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 12
17 COSM149276742 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1753G>A p.G585S 16:72958393-72958393 12
18 COSM87277220 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 12
19 COSM87275783 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1411G>A p.E471K 16:72958735-72958735 12
20 COSM102020207 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4078C>T p.Q1360* 16:72795862-72795862 12
21 COSM102043844 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6219G>T p.K2073N 16:72793721-72793721 12
22 COSM149319798 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 12
23 COSM149259590 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1936G>A p.D646N 16:72958210-72958210 12
24 COSM87271751 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 12
25 COSM102042266 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8224C>T p.P2742S 16:72787310-72787310 12
26 COSM149286811 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 12
27 COSM149314151 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 12
28 COSM149261368 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4342C>A p.L1448I 16:72798340-72798340 12
29 COSM87283861 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3271G>A p.V1091I 16:72889908-72889908 12
30 COSM87292093 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2459G>A p.R820H 16:72957687-72957687 12
31 COSM102022012 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1832T>C p.L611P 16:72798108-72798108 12
32 COSM149284453 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4653G>T p.K1551N 16:72798029-72798029 12
33 COSM87278783 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8152G>A p.A2718T 16:72794530-72794530 12
34 COSM87292968 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 12
35 COSM102043873 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.655G>A p.E219K 16:72889782-72889782 12
36 COSM102036330 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.-23-7212G>A p.? 16:72958177-72958177 12
37 COSM149265910 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 12
38 COSM149292038 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8633C>T p.A2878V 16:72794049-72794049 12
39 COSM149293431 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 12
40 COSM149281700 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8617G>A p.E2873K 16:72794065-72794065 12
41 COSM87293150 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3193G>A p.E1065K 16:72950492-72950492 12
42 COSM87289627 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 12
43 COSM87285871 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 12
44 COSM102045840 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.-23-9018G>A p.? 16:72959983-72959983 12
45 COSM149322559 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2861C>T p.T954M 16:72950824-72950824 12
46 COSM87293131 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8961G>T p.K2987N 16:72793721-72793721 12
47 COSM149264593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.629G>A p.G210D 16:72959517-72959517 12
48 COSM102023623 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1183C>T p.R395* 16:72800069-72800069 12
49 COSM149261344 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 12
50 COSM149280950 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2770T>G p.S924A 16:72950915-72950915 12

Expression for Endometrial Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Adenocarcinoma.

Pathways for Endometrial Adenocarcinoma

Pathways related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VEGFA TP53 PTEN PGR MLH1 ESR2
2
Show member pathways
13.89 VEGFA TP53 PTEN PIK3R2 KRAS FGFR2
3
Show member pathways
13.77 VEGFA TP53 PIK3R2 KRAS FGFR2 ESR2
4
Show member pathways
13.43 VEGFA TP53 PIK3R2 KRAS FGFR2 EGFR
5
Show member pathways
13.36 VEGFA PIK3R2 KRAS FGFR2 ESR2 ESR1
6
Show member pathways
13.19 TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
7
Show member pathways
13.16 VEGFA TP53 PTEN PIK3R2 KRAS EGFR
8
Show member pathways
13.16 TP53 PTEN PIK3R2 KRAS FGFR2 EGFR
9
Show member pathways
13.05 VEGFA TP53 PTEN PIK3R2 KRAS FGFR2
10
Show member pathways
13.02 VEGFA TP53 PIK3R2 KRAS EGFR CDKN2A
11
Show member pathways
12.99 VEGFA PTEN PIK3R2 KRAS EGFR AKT1
12
Show member pathways
12.95 PTEN PIK3R2 KRAS FGFR2 EGFR AKT1
13
Show member pathways
12.94 VEGFA PTEN PIK3R2 KRAS EGFR AKT1
14
Show member pathways
12.91 TP53 PTEN PIK3R2 KRAS EGFR AKT1
15 12.85 VEGFA TP53 KRAS FGFR2 EGFR AKT1
16
Show member pathways
12.82 VEGFA PIK3R2 KRAS FGFR2 EGFR AKT1
17
Show member pathways
12.8 TP53 PTEN PIK3R2 KRAS FGFR2 EGFR
18
Show member pathways
12.79 TP53 PIK3R2 KRAS CDKN2A AKT1
19
Show member pathways
12.79 TP53 PTEN PIK3R2 KRAS ESR1 AKT1
20
Show member pathways
12.79 VEGFA TP53 PTEN PIK3R2 MLH1 KRAS
21
Show member pathways
12.76 TP53 PIK3R2 MLH1 KRAS AKT1
22
Show member pathways
12.75 TP53 PIK3R2 KRAS EGFR AKT1
23
Show member pathways
12.74 VEGFA PIK3R2 KRAS EGFR CDKN2A AKT1
24
Show member pathways
12.69 PTEN PIK3R2 KRAS EGFR AKT1
25
Show member pathways
12.68 TP53 PIK3R2 KRAS EGFR AKT1
26
Show member pathways
12.68 VEGFA PTEN PIK3R2 KRAS AKT1
27
Show member pathways
12.57 PTEN PIK3R2 KRAS ESR2 ESR1 AKT1
28
Show member pathways
12.57 TP53 PTEN PIK3R2 KRAS FGFR2 EGFR
29
Show member pathways
12.56 VEGFA TP53 PTEN PIK3R2 KRAS FGFR2
30
Show member pathways
12.56 TP53 PTEN PIK3R2 KRAS FGFR2 ESR2
31
Show member pathways
12.53 TP53 PIK3R2 KRAS FGFR2 EGFR AKT1
32 12.51 VEGFA TP53 PTEN PIK3R2 MIR34A MIR200A
33
Show member pathways
12.5 VEGFA PIK3R2 KRAS EGFR AKT1
34
Show member pathways
12.5 VEGFA PIK3R2 KRAS ESR1 AKT1
35
Show member pathways
12.48 PTEN PIK3R2 KRAS AKT1
36 12.48 TP53 PIK3R2 EGFR AKT1
37
Show member pathways
12.48 PIK3R2 KRAS FGFR2 AKT1
38
Show member pathways
12.47 PIK3R2 KRAS EGFR AKT1
39
Show member pathways
12.47 TP53 PTEN PIK3R2 AKT1
40 12.46 VEGFA TP53 PTEN PIK3R2 MLH1 KRAS
41
Show member pathways
12.44 PIK3R2 PGR KRAS AKT1
42
Show member pathways
12.43 VEGFA TP53 PTEN KRAS FGFR2 EGFR
43 12.42 TP53 PTEN PIK3R2 KRAS CDKN2A AKT1
44
Show member pathways
12.41 PIK3R2 KRAS EGFR AKT1
45
Show member pathways
12.41 PIK3R2 ESR2 ESR1 EGFR AKT1
46
Show member pathways
12.39 TP53 PTEN EGFR AKT1
47
Show member pathways
12.39 VEGFA TP53 KRAS EGFR AKT1
48 12.38 TP53 PIK3R2 KRAS CDKN2A
49 12.38 VEGFA TP53 PIK3R2 KRAS ESR1 EGFR
50
Show member pathways
12.36 TP53 KRAS FGFR2 EGFR AKT1

GO Terms for Endometrial Adenocarcinoma

Biological processes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.08 TP53 ESR2 ESR1 EGFR CDKN2A AKT1
2 cellular response to DNA damage stimulus GO:0006974 10.06 TP53 MLH1 MIR34A MIR193A AKT1
3 positive regulation of cell proliferation GO:0008284 10 VEGFA PTEN KRAS FGFR2 EGFR AKT1
4 positive regulation of apoptotic process GO:0043065 9.97 TP53 PTEN MIR204 CDKN2A AKT1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 VEGFA PTEN FGFR2 EGFR
6 positive regulation of protein phosphorylation GO:0001934 9.93 VEGFA KRAS EGFR AKT1
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.88 PTEN PGR ESR2 ESR1
8 Ras protein signal transduction GO:0007265 9.82 TP53 KRAS CDKN2A
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.81 PTEN MIR193A CDKN2A
10 negative regulation of protein kinase B signaling GO:0051898 9.81 PTEN MIR34A AKT1
11 positive regulation of epithelial cell proliferation GO:0050679 9.8 VEGFA FGFR2 EGFR
12 negative regulation of gene expression GO:0010629 9.8 VEGFA TP53 PGR MIR34A ESR1 AKT1
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 FGFR2 EGFR AKT1
14 positive regulation of MAP kinase activity GO:0043406 9.79 VEGFA KRAS EGFR
15 positive regulation of protein kinase B signaling GO:0051897 9.77 VEGFA PIK3R2 FGFR2 ESR1 EGFR
16 positive regulation of DNA-binding transcription factor activity GO:0051091 9.76 PTEN ESR2 ESR1 AKT1
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.74 VEGFA MIR200A AKT1
18 cellular response to estradiol stimulus GO:0071392 9.72 ESR2 ESR1 EGFR
19 phosphatidylinositol 3-kinase signaling GO:0014065 9.71 PTEN PIK3R2 AKT1
20 positive regulation of gene expression GO:0010628 9.7 VEGFA TP53 PTEN MIR34A KRAS CDKN2A
21 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.66 TP53 ESR1
22 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.65 TP53 ESR1
23 negative regulation of cell size GO:0045792 9.65 PTEN AKT1
24 positive regulation of cell cycle arrest GO:0071158 9.65 TP53 MIR34A CDKN2A
25 positive regulation of transcription by RNA polymerase II GO:0045944 9.65 VEGFA TP53 PIK3R2 PGR FGFR2 ESR2
26 positive regulation of cellular senescence GO:2000774 9.61 MIR34A KRAS CDKN2A
27 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.6 VEGFA TP53
28 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.59 FGFR2 ESR1
29 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.58 TP53 PTEN MIR34A
30 cellular response to decreased oxygen levels GO:0036294 9.56 PTEN AKT1
31 response to UV-A GO:0070141 9.51 EGFR AKT1
32 prostate epithelial cord elongation GO:0060523 9.49 FGFR2 ESR1
33 intracellular steroid hormone receptor signaling pathway GO:0030518 9.43 PGR ESR2 ESR1
34 cellular response to hypoxia GO:0071456 9.1 VEGFA TP53 PTEN MIR34A MALAT1 AKT1

Molecular functions related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.85 VEGFA TP53 PTEN PGR KRAS FGFR2
2 protein kinase binding GO:0019901 9.8 TP53 PTEN ESR1 EGFR CDKN2A AKT1
3 nuclear receptor activity GO:0004879 9.63 PGR ESR2 ESR1
4 steroid binding GO:0005496 9.54 PGR ESR2 ESR1
5 MDM2/MDM4 family protein binding GO:0097371 9.48 TP53 CDKN2A
6 estrogen receptor activity GO:0030284 9.43 ESR2 ESR1
7 steroid hormone receptor activity GO:0003707 9.43 PGR ESR2 ESR1
8 estrogen response element binding GO:0034056 9.4 ESR2 ESR1
9 enzyme binding GO:0019899 9.23 TP53 PTEN PGR MLH1 ESR2 ESR1
10 nitric-oxide synthase regulator activity GO:0030235 9.13 ESR1 EGFR AKT1

Sources for Endometrial Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....